拜瑞妥治疗效果怎么样？

(Rivaroxaban) is a highly selective, oral drug that directly inhibits Factor Xa. By inhibiting factor Xarelto does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by Xarelto has been observed in humans.

Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, with the trade name Xarelto. It has been approved for marketing in many countries and is used to prevent venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. It is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

So how effective is Xarelto treatment?

Eisenberg MJ et al. meta-analyzed five randomized controlled studies (a total of 23,063 patients were included, all of whom took Xarelto for ≥1 month, including 14,264 cases of non-valvular atrial fibrillation, 3967 cases of deep vein thrombosis, and 3967 cases of acute symptomatic pulmonary embolism).

  The results found that compared with vitamin K antagonists, Xarelto did not increase the composite endpoint of major bleeding and clinically relevant bleeding (RR: 0.99, confidence interval: 0.93-1.06), and, in the Xarelto group, fatal bleeding events were significantly reduced (RR: 0.48, confidence interval: 0.31-0.74).

A newly published study shows that a new anticoagulant drug from Bayer Healthcare of Germany can effectively reduce the formation of venous thrombosis in patients after major orthopedic surgery, and its efficacy is better than the current standard treatment of enoxaparin.